The results were consistent with the animal level, suggesting that VEGFB may participate in the AMPK signaling pathway and lipid metabolism of NAFLD through CaMKKβ. This evidence concerns the gene CAMKK2 and metabolic dysfunction-associated steatotic liver disease.